Amyris (NASDAQ:AMRS) issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.24), Yahoo Finance reports. The firm had revenue of $80.59 million for the quarter, compared to analyst estimates of $68.14 million. The business’s quarterly revenue was up 262.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.09) earnings per share.
Shares of AMRS stock traded down $0.27 during trading hours on Friday, reaching $6.79. 561,376 shares of the stock were exchanged, compared to its average volume of 943,009. The company has a debt-to-equity ratio of -0.78, a quick ratio of 0.82 and a current ratio of 0.92. Amyris has a 12-month low of $1.86 and a 12-month high of $10.65. The firm has a market capitalization of $303.82, a price-to-earnings ratio of -2.23 and a beta of 0.13.
In related news, insider John Melo sold 10,776 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total transaction of $50,431.68. Following the sale, the insider now directly owns 83,172 shares in the company, valued at $389,244.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 11.30% of the stock is currently owned by corporate insiders.
Several brokerages have recently issued reports on AMRS. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Amyris in a research report on Monday, April 2nd. ValuEngine cut shares of Amyris from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Finally, B. Riley began coverage on shares of Amyris in a research report on Thursday, January 25th. They set a “buy” rating and a $8.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $8.19.
ILLEGAL ACTIVITY WARNING: “Amyris (NASDAQ:AMRS) Posts Earnings Results, Misses Expectations By $0.24 EPS” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/amyris-amrs-issues-quarterly-earnings-results.html.
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.